American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 418.e1-418.e7 , April 2008

Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary

  • Elin Ødegaard, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Ben Davidson, MD, PhD

      Affiliations

    • Department of Pathology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
    • ,
  • Bente Vilming Elgaaen, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Magne K. Fagerhol, MD, PhD

      Affiliations

    • Department of Immunology and Transfusion Medicine, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway.
    • ,
  • Vibeke Engh, MD

      Affiliations

    • Department of Pathology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Mathias Onsrud, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway.
    • ,
  • Anne Cathrine Staff, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway.

Received 18 June 2007 ,Revised 3 October 2007 ,Accepted 11 October 2007.

References 

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Winter WE, Kucera PR, Rodgers W, McBroom JW, Olsen C, Maxwell GL. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol. 2002;100:671–676
  3. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–1518
  4. Fagerhol MK. Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein?. Clin Mol Pathol. 1996;49:M74–M79
  5. Fagerhol MK, Dale I, Andersson T. Release and quantitation of a leucocyte derived protein (L1). Scand J Haematol. 1980;24:393–398
  6. Odink K, Cerletti N, Bruggen J, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature. 1987;330:80–82
  7. Hermani A, Hess J, De Servi B, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005;11:5146–5152
  8. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72:1622–1631
  9. Ott HW, Lindner H, Sarg B, et al. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res. 2003;63:7507–7514
  10. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990;336:763–765
  11. Kocher M, Kenny PA, Farram E, Abdul Majid KB, Finlay-Jones JJ, Geczy CL. Functional chemotactic factor CP-10 and MRP-14 are abundant in murine abscesses. Infect Immun. 1996;64:1342–1350
  12. Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet. 2000;356:1783–1784
  13. Murao S, Collart FR, Huberman E. A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J Biol Chem. 1989;264:8356–8360
  14. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003;26:753–760
  15. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–21494
  16. El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002;62:6823–6826
  17. Arai K, Yamada T, Nozawa R. Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol. 2000;17:183–188
  18. Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer. 2004;40:1179–1187
  19. Dale I, Brandtzaeg P. Expression of the epithelial L1 antigen as an immunohistochemical marker of squamous cell carcinoma of the lung. Histopathology. 1989;14:493–502
  20. Kristinsson J, Roseth A, Fagerhol MK, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum. 1998;41:316–321
  21. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999;93:448–452
  22. Trope C, Kaern J. Management of borderline tumors of the ovary: state of the art. Semin Oncol. 1998;25:372–380
  23. Terry KL, Sluss PM, Skates SJ, et al. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers. 2004;20:53–70
  24. Yurkovetsky ZR, Linkov FY, Malehorn E, Lokshin AE. Multiple biomarker panels for early detection of ovarian cancer. Future Oncol. 2006;2:733–741
  25. Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics. 2007;4:121–131
  26. Agarwal R, Whang DH, Alvero AB, et al. Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol. 2007;196:348–355

 The work of E.Ø. is supported by research grants from Ulleval University Hospital (Vitenskapsradet Ulleval universitetssykehus) and the Eastern Norway Regional Health Authority.

 Reprints not available from the authors.

 Cite this article as: Ødegaard E, Davidson B, Elgaaen BV, et al. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol 2008;198:418.e1-418.e7.

PII: S0002-9378(07)02014-5

doi: 10.1016/j.ajog.2007.10.792

American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 418.e1-418.e7 , April 2008

Article Tools

* Image Usage & Resolution